Cagrilintide (AM833) is a synthetic long-acting lipidated analog of amylin, a 37-amino-acid peptide that acts as a dual amylin and calcitonin receptor agonist. Research investigations have focused on its potential for weight management, with Phase 3 clinical trials examining its efficacy both as monotherapy and in combination with semaglutide (CagriSema).
In clinical research settings, cagrilintide has been studied for its effects on appetite regulation and metabolic parameters. Published investigations have examined its extended pharmacokinetic profile, with a half-life supporting once-weekly administration. Studies have explored its mechanism of action through subcutaneous delivery, targeting satiety pathways and metabolic processes via amylin and calcitonin receptor activation.
Supplied as a lyophilized powder for reconstitution. Intended for research purposes only.
